A small Italian pharmaceutical company that is now part of a larger European entity sought Aptuit’s assistance in the development of a drug product treating inflammatory and auto immune diseases. Because of the low solubility of the API, the client was looking to identify a formulation with improved bioavailability. The decision to work with Aptuit was enhanced

Aptuit has successfully completed several anti-sense oligonucleotides projects in various phases of clinical studies for three pharmaceutical companies. These projects required method development, phase appropriate validation and longterm stability studies of their drug substances and drug products, and testing of the in-process samples.

Aptuit has extensive experience in analyzing large molecules such as proteins, peptid....  Read More

Since 2008, Exelixis and Aptuit have been engaged in a long term strategic partnership that represents a new paradigm in pharmaceutical relationships. From the beginning, Aptuit has brought to the relationship a real understanding of Exelixis’ goal to redefine the way cancer drugs are discovered and developed, fundamentally changing the way cancer patients are treated.

Now part of a larger pharmaceutical entity, a European company engaged Aptuit in the development of a Phase I oncology study focused on capsule formulation of a cytostatic highly potent compound. The project was designed to improve the bioavailability of an immediate release capsule.

As a drug product enters into the later clinical phases, there is a requirement to support large registration stability studies. A large European client sought Aptuit’s substantial resources to conduct large scale stability testing. Although there are a few other service providers with the capabilities to support large pharmaceutical organizations in these studies, Aptuit offers an added competency because of its large team of dedicat....  Read More